The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Beyond antiresorptive medications, anabolic bone-building medications, including teriparatide, abaloparatide (Tymlos), and ...

Some of the most commonly used medications for osteoporosis can lead to osteonecrosis of the jaw (ONJ), a rare but serious side effect.

Bisphosphonates have long been established as critical agents in the treatment of bone disorders, yet recent innovations in their green synthesis are paving the way for more sustainable, efficient, ...